Whitepaper
21 May 2026
Time-to-Market
PDF 1.4 MB
Faster time-to-market for lyophilized drugs and vaccines thanks to the RheaLyo™
Continuous Freeze-Drying Technology
Content provided by our supplier
RheaVita
-
Country/Region:Belgium
-
On CPHI since:2023
-
Certificates:1
-
Employees:1 - 24
Company types
Primary activities
Other Content from RheaVita (4)
-
Whitepaper ADC
Advancing ADC Lyophilization: The Value of RheaVita’s RheaLyo™ Continuous Freeze-Drying Technology for Antibody–Drug Conjugates (ADCs)
-
Brochure RheaVita overview
Summary of our products and services. -
Brochure BSL2
The Mono freeze-dryer expanded with a BSL-2 option. -
Whitepaper mRNA LNP
Stabilizing mRNA LNPs via controlled continuous freeze-drying